Acurex Biosciences Analysis
What is Acurex Biosciences?
Acurex Biosciences focuses on developing therapies for neurodegenerative diseases, particularly Parkinson's disease, using a proprietary platform based on a Stanford University discovery. Their lead drug candidate, CU-13001, is designed to penetrate the brain and alter disease progression.
Location
930 Brittan Avenue, San Carlos, California 94070, United States
Employees
11-50
Founded
2019
Funding Status
Series B
Product Features & Capabilities
- CU-13001 oral small molecule for Parkinson's disease
- M3D platform for druggable target identification
- Miro1 biomarker for neurological disease detection
Use Cases
Targeting Parkinson's disease progression with CU-13001; Identifying druggable targets for neurological diseases; Detecting biomarker changes in patients; Developing early-stage neurology drug candidates; Supporting research with funding from major foundations
Other Considerations
Supported by Stanford University and major foundations; Funded by the Michael J. Fox Foundation; Collaborations with Parkinson's UK and the National Institute on Aging
See something that needs updating? Suggest edits to this profile.